14Jul 2020

DEVELOPMENT OF QUALITY STANDARDS OF BEHIDANA- A PROPHYLAXIS UNANI SINGLE DRUG USED FOR MANAGEMENT OF COVID-19

  • Central Council for Research in Unani Medicine, M/O Ayush, Govt. of India, New Delhi.
  • Regional Research Institute of Unani Medicine, Royapuram, Chennai, India.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • Cite This Article as
  • Corresponding Author

The COVID-19 pandemic is threatening the worldwide population. A huge population of world is suffering from this disease and no specific vaccine for this pandemic disease has been developed.The main symptoms of this disease are fever, cough, shortness of breathand tirednessetc. The Ministry of AYUSH has issued various guidelines to prevent this disease by taking immunity boosters and prophylaxis as defence against any disease. In Unani system of medicines, many drugs of plant origin are mentioned in classical literature for strengthening and increasing the immunity of humans. Since, the drug Behidana is being given to COVID-19 patients as prophylaxis regime, it has become necessary to authenticate and develop its pharmacopoeial standards so that quality raw material can be provided to needy mass. The present study is aimed to develop identity, purity and strength of drug using pharmacognostical, physico-chemical and quality control methods.


[Sadaf Subhani, R.P.Meena, Asim Ali Khan, S. Mageswasri and P. Meera Devi Sri (2020); DEVELOPMENT OF QUALITY STANDARDS OF BEHIDANA- A PROPHYLAXIS UNANI SINGLE DRUG USED FOR MANAGEMENT OF COVID-19 Int. J. of Adv. Res. 8 (Jul). 1216-1225] (ISSN 2320-5407). www.journalijar.com


SADAF SUBHANI
CENTRAL COUNCIL FOR RESEARCH IN UNANI MEDICINE
India

DOI:


Article DOI: 10.21474/IJAR01/11389      
DOI URL: http://dx.doi.org/10.21474/IJAR01/11389